Dataset Information

Attitudes toward molecular testing for personalized cancer therapy.

ABSTRACT: This study assessed attitudes of breast cancer patients toward molecular testing for personalized therapy and research.A questionnaire was given to female breast cancer patients presenting to a cancer center. Associations between demographic and clinical variables and attitudes toward molecular testing were evaluated.Three hundred eight patients were approached, and 100 completed the questionnaire (a 32% response rate). Most participants were willing to undergo molecular testing to assist in the selection of approved drugs (81%) and experimental therapy (59%) if testing was covered by insurance. Most participants were white (71%). Even if testing was financially covered, nonwhite participants were less willing to undergo molecular testing for the selection of approved drugs (54% of nonwhites vs 90% of whites, odds ratio [OR]?=?0.13, P?=?.0004) or experimental drugs (35% vs 68%, OR?=?0.26, P?=?.0072). Most participants (75%) were willing to undergo a biopsy to guide therapy, and 46% were willing to undergo research biopsies. Nonwhite participants were less willing to undergo research biopsies (17% vs 55%, OR?=?0.17, P?=?.0033). Most participants wanted to be informed when research results had implications for treatment (91%), new cancer risk (90%), and other preventable/treatable diseases (87%).Most patients were willing to undergo molecular testing and minimally invasive procedures to guide approved or experimental therapy. There were significant differences in attitudes toward molecular testing between racial groups; nonwhites were less willing to undergo testing even if the results would guide their own therapy. Novel approaches are needed to prevent disparities in the delivery of genomically informed care and to increase minority participation in biomarker-driven trials. Cancer 2015;121:243-50. © 2014 American Cancer Society.

SUBMITTER: Yusuf RA

PROVIDER: S-EPMC4293219 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Attitudes toward molecular testing for personalized cancer therapy.

Yusuf Rafeek A RA Rogith Deevakar D Hovick Shelly R A SR Peterson Susan K SK Burton-Chase Allison M AM Fellman Bryan M BM Li Yisheng Y McKinney Carolyn C Bernstam Elmer V EV Meric-Bernstam Funda F

Cancer 20140910 2

<h4>Background</h4>This study assessed attitudes of breast cancer patients toward molecular testing for personalized therapy and research.<h4>Methods</h4>A questionnaire was given to female breast cancer patients presenting to a cancer center. Associations between demographic and clinical variables and attitudes toward molecular testing were evaluated.<h4>Results</h4>Three hundred eight patients were approached, and 100 completed the questionnaire (a 32% response rate). Most participants were wi ...[more]

PMID: 25209923

Similar Datasets

Project description:BackgroundThe strong association between family history and prostate cancer (PCa) suggests a significant genetic contribution, yet specific highly penetrant PCa susceptibility genes have not been identified. Certain single-nucleotide-polymorphisms have been found to correlate with PCa risk; however uncertainty remains regarding their clinical utility and how to best incorporate this information into clinical decision-making. Genetic testing is available directly to consumers and both patients and healthcare providers are becoming more aware of this technology. Purchasing online allows patients to bypass their healthcare provider yet patients may have difficulty interpreting test results and providers may be called upon to interpret results. Determining optimal ways to educate both patients and providers, and strategies for appropriately incorporating this information into clinical decision-making are needed.MethodsA mixed-method study was conducted in Utah between October 2011 and December 2011. Eleven focus group discussions were held and surveys were administered to 23 first-degree relatives of PCa patients living in Utah and 24 primary-care physicians and urologists practicing in Utah to present specific information about these assessments and determine knowledge and attitudes regarding health implications of using these assessments.ResultsData was independently coded by two researchers (relative Kappa = .88; provider Kappa = .77) and analyzed using a grounded theory approach. Results indicated differences in attitudes and behavioral intentions between patient and provider. Despite the test's limitations relatives indicated interest in genetic testing (52%) while most providers indicated they would not recommend the test for their patients (79%). Relatives expected providers to interpret genetic test results and use results to provide personalized healthcare recommendations while the majority of providers did not think the information would be useful in patient care (92%) and indicated low-levels of genetic self-efficacy.ConclusionsAlthough similarities exist, discordance between provider and patient attitudes may influence the effective translation of novel genomic tests into clinical practice suggesting both patient and provider perceptions and expectations be considered in development of clinical decision-support tools.

Dataset Information

Attitudes toward molecular testing for personalized cancer therapy.

Publications

Attitudes toward molecular testing for personalized cancer therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets